Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

Cancer Cell

Volumn 1, Issue 5, 2002, Pages 413-415

  Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CEP 701; FLT3 LIGAND; IMATINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SUNITINIB; UNCLASSIFIED DRUG; CD135 ANTIGEN; CELL SURFACE RECEPTOR; ENZYME INHIBITOR; FLT3 PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; DRUG CONFORMATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE FUSION; GENE MUTATION; HUMAN; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; SHORT SURVEY; TRANSCRIPTION TERMINATION; ACUTE DISEASE; DRUG ANTAGONISM; MYELOID LEUKEMIA; REVIEW;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE;

EID: 0036595322     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00080-6     Document Type: Review

References (28)

1. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K.P., and Hughes, T.P. (2002). Blood 99, 3472-3475.
2. Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Science 247, 824-830.
3. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., and Talpaz, M. (2001a). N. Engl. J. Med. 344, 1038-1042.
4. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C.L. (2001b). N. Engl. J. Med. 344, 1031-1037.
5. Fabbro, D., Buchdunger, E., Wood, J., Mestan, J., Hofmann, F., Ferrari, S., Mett, H., O'Reilly, T., and Meyer, T. (1999). Pharmacol. Ther. 82, 293-301.
6. Fong, T.A., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., Schreck, R., Wang, X., Risau, W., et al. (1999). Cancer Res. 59, 99-106.
7. George, D.J., Dionne, C.A., Jani, J., Angeles, T., Murakata, C., Lamb, J., and Isaacs, J.T. (1999). Cancer Res. 59, 2395-2401.
8. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., and Sawyers, C.L. (2001). Science 293, 876-880.
9. Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., and Naoe, T. (2000). Oncogene 19, 624-631.
10. Huse, M., and Kuriyan, J. (2002). Cell 109, 275-282.
11. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002). N. Engl. J. Med. 346, 645-652.
12. Kelly, L., Clark, J., and Gilliland, D.G. (2002a). Curr. Opin. Oncol. 14, 10-18.
13. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L., and Gilliland, D.G. (2002b). Blood 99, 310-318.
14. Kelly, L.M., Yu, J.-C., Boulton, C.L., Apatira, M., Li, J., Sullivan, C.M., Williams, I., Amaral, S.M., Curley, D.P., Duclos, N., et al. (2002c). Cancer Cell, this issue, 421-432.
15. Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999). Blood 93, 3074-3080.
16. Levis, M., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. (2002). Blood 99, 3885-3891.
17. Levis, M., Tse, K.F., Smith, B.D., Garrett, E., and Small, D. (2001). Blood 98, 885-887.
18. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., and Misawa, S. (1996). Leukemia 10, 1911-1918.
19. O'Farrell, A.M., Abrams, T., Yuen, H., Ngai, T., Louie, S., Wong, L., Heinrich, M., Yee, K., Smolich, B., Murray, L., et al. (2001). SUGEN Compounds SU5416 and SU11248 Inhibit FltS Activity: Therapeutic Application in AML. American Society of Hematology 43rd Annual Meeting, Orlando, Florida.
20. Propper, D.J., McDonald, A.C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J.P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001). J. Clin. Oncol. 19, 1485-1492.
21. Sawyers, C.L. (1999). N. Engl. J. Med. 340, 1330-1340.
22. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W., et al. (2002). Blood 99, 3530-3539.
23. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kuriyan, J. (2000). Science 289, 1938-1942.
24. Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C.A., Fischer, T., Deininger, M.W., Lennard, A.L., et al. (2002). Blood 99, 1928-1937.
25. von Bubnoff, N., Schneller, F., Peschel, C., and Duyster, J. (2002). Lancet 359, 487-491.
26. Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G., and Griffin, J.D. (2002). Cancer Cell, this issue, 433-443.
27. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., et al. (2001). Blood 97, 2434-2439.
28. Yee, K.W.H., O'Farrell, A.M., Smolich, B.D., Cherrington, J.M., Wait, C.L., Griffith, D.J., McGreevey, L.S., and Heinrich, M.C. (2001). SU5416 and SU5614 Inhibit Wild-Type and Activated Mutant FLT3 Signaling in Leukemia Cells. American Society of Hematology 43rd Annual Meeting, Orlando, Florida.